Citius Pharma ( (CTXR) ) has released its Q1 earnings. Here is a breakdown of the information Citius Pharma presented to its investors.
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing first-in-class critical care products, with a notable emphasis on targeted immunotherapies and treatments for catheter-related bloodstream infections.
In its fiscal first quarter of 2025, Citius Pharma reported significant advancements in its operational readiness for the commercial launch of LYMPHIR, a targeted immunotherapy. The company also secured a new permanent J-code for LYMPHIR, indicating progress in its commercialization efforts. Additionally, promising preliminary results were announced from a Phase I clinical trial involving LYMPHIR and pembrolizumab for recurrent solid tumors.
Key financial metrics from the quarter include a net loss of $10.3 million, or $1.30 per share, compared to a net loss of $9.2 million, or $1.45 per share, in the same quarter of the previous year. The company reported cash and cash equivalents of $1.1 million as of December 31, 2024. Research and development expenses decreased to $2.1 million, while general and administrative expenses increased to $5.4 million, attributed to pre-launch activities for LYMPHIR.
Citius Pharma continues to engage with the FDA to clarify development paths for its pipeline assets, Mino-Lok and Halo-Lido. The company also completed several financing initiatives, raising $6.5 million through equity offerings to support its clinical and commercial programs.
Looking ahead, Citius Pharma is focused on the anticipated launch of LYMPHIR in the first half of 2025 and is actively pursuing strategic partnerships and financing options to strengthen its financial position and support its growth initiatives.